Effect of the IP10 (CXCL10) and HLA genotype on the risk of type 1 diabetes in children

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 17, Issue 1, 2011, Pages 10-13

  Klich, Izabela ^a   Fendler, Wojciech ^a   Wyka, Krystyna ^a   Młynarski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chemokines; Children; Type 1 diabetes

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; HLA DQ8 ANTIGEN; INSULIN;

3' UNTRANSLATED REGION; ARTICLE; AUTOIMMUNITY; CHILD; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE COURSE; FEMALE; GENE INTERACTION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PROTEIN FUNCTION; RISK REDUCTION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84904852322     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bruck P., Bartsch W., Penna-Martinez M. et al.: Polymorphisms of CXCR3-binding chemokines in type 1 diabetes. Hum. Immunol., 2009, 70, 552-555.
2. Rhode A., Pauza M.E., Barral A.M. et al.: Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J. Immunol., 2005, 175, 3516-3524.
3. Roep B.O., Kleijwegt F.S., van Halteren A.G. et al.: Islet inflammation and CXCL10 in recentonset type 1 diabetes. Clin. Exp. Immunol., 2010, 159, 338-343.
4. Morimoto J., Yoneyama H., Shimada A. et al.: CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. J. Immunol., 2004, 173, 7017-7024.
5. Shanmugam N., Ransohoff R.M., Natarajan R.: Interferon-gamma-inducible protein (IP)-10 mRNA stabilized by RNA-binding proteins in monocytes treated with S100b. J. Biol. Chem., 2006, 281, 31212-31221.
6. Laine P.S., Schwartz E.A., Wang Y. et al.: Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. Biochem. Biophys. Res. Commun., 2007, 358, 150-155.
7. Berg A.K., Korsgren O., Frisk G.: Induction of the chemokine interferon-gamma-inducible protein-10 in human pancreatic islets during enterovirus infection. Diabetologia, 2006, 49, 2697-2703.
8. Krokowski M., Bodalski J., Bratek A. et al.: HLA class II-associated predisposition to insulin-dependent diabetes mellitus in a Polish population. Hum. Immunol., 1998, 59, 451-455.
9. Frazer K.A., Ballinger D.G., Cox D.R. et al.: A second generation human haplotype map of over 3.1 million SNPs. Nature, 2007, 449, 851-861.
10. Shigihara T., Shimada A., Oikawa Y. et al.: CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. J. Immunol., 2005, 175, 8401-8408.
11. Shen Q., Zhang R., Bhat N.R.: MAP kinase regulation of IP10/CXCL10 chemokine gene expression in microglial cells. Brain Res., 2006, 1086, 9-16.
12. Loetscher P., Pellegrino A., Gong J.H. et al.: The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem., 2001, 276, 2986-2991.
13. XCL10 (chemokine (C-X-C motif) ligand 10). http://biogps.gnf.org/#goto= genereport&id=3627, 2011-01-11.